Clinical Trial

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: * CB-103 (an oral NOTCH pathway inhibitor) * Abemaciclib (CDK4/6 inhibitor) * Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI))
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-03-14; most recent amendment 2026-06-25.
Status change: Active, Not Recruiting → Recruiting 2025-06-16
Status change: Recruiting → Active, Not Recruiting 2024-10-01
Status change: Not Yet Recruiting → Recruiting 2023-06-01
Trial Details
NCT Number NCT05774899
Lead Sponsor Glenn J. Hanna
Collaborators: Adenoid Cystic Carcinoma Research Foundation, Cellestia Biotech AG
Conditions Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
Enrollment 32 participants
Start Date 2023-06-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-29